Bone and Joint Institute
Rho/ROCK and MEK/ERK activation by transforming growth factor-α induces articular cartilage degradation
Document Type
Article
Publication Date
1-1-2010
Journal
Laboratory Investigation
First Page
20
Last Page
30
URL with Digital Object Identifier
10.1038/labinvest.2009.111
Abstract
Identification and characterization of therapeutic targets for joint conditions, such as osteoarthritis (OA), is exceedingly important for addressing the increasing burden of disease. Transforming growth factor-α (TGFα) is upregulated by articular chondrocytes in experimentally induced and human OA. To test the potential involvement of TGFα, which is an activator of epidermal growth factor receptor (EGFR) signaling, in joint degeneration and to identify signaling mechanisms mediating articular chondrocyte responses to TGFα, rat chondrocytes and osteochondral explants were treated with TGFα and various inhibitors of intracellular signaling pathways. Stimulation of EGFR signaling in articular chondrocytes by TGFα resulted in the activation of RhoA/ROCK (Rho kinase), MEK (MAPK/ERK kinase)/ERK (extracellular-signal-regulated kinase), PI3K (phosphoinositide 3-kinase) and p38 MAPK (mitogen-activated protein kinase) pathways. Modification of the chondrocyte actin cytoskeleton was stimulated by TGFα, but inhibition of only Rho or ROCK activation prevented morphological changes. TGFα suppressed expression of anabolic genes including Sox9, type II collagen and aggrecan, which were rescued only by inhibiting MEK/ERK activation. Furthermore, catabolic factor upregulation by TGFα was prevented by ROCK and p38 MAPK inhibition, including matrix metalloproteinase-13 and tumor necrosis factor-α, which are well known to contribute to cartilage digestion in OA. To assess the ability of TGFα to stimulate degradation of mature articular cartilage, type II collagen and aggrecan cleavage fragments were analyzed in rat osteochondral explants exposed to exogenous TGFα. Normal articular cartilage contained low levels of both cleavage fragments, but high levels were observed in the cartilage treated with TGFα. Selective inhibition of MEK/ERK and Rho/ROCK activation greatly reduced or completely prevented excess type II collagen and aggrecan degradation in response to TGFα. These data suggest that TGFα is a strong stimulator of cartilage degradation and that Rho/ROCK and MEK/ERK signaling have critical roles in mediating these effects. © 2010 USCAP, Inc All rights reserved.
Notes
This article is freely available from the journal.